Cell Biology

Lexigen Signs On As 19th PER.C6 Licensee

Published in Vaccine Weekly, February 13th, 2002

Dutch antibody and vaccine company Crucell (CRXL) has granted Boston-based Lexigen Pharmaceuticals Corp. a nonexclusive license for its proprietary human cell system PER.C6.

Under the terms of the agreement, Lexigen will use PER.C6 for research and clinical development of therapeutics in the field of oncology. Crucell will receive upfront and annual payments, while Lexigen has an option for a commercial license. Further financial details were not disclosed.

According to Crucell's CEO Dinko Valerio, the deal strengthens the position of PER.C6 as the industry standard for the production of gene therapy and vaccine products. "An increasing number of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2002-02-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry